Crispr Therapeutics Reports A Patient Death In Lymphoma Therapy Clinical Trial

Crispr Therapeutics Reports A Patient Death In Lymphoma Therapy Clinical Trial

Crispr Therapeutics said a patient in a Phase 1 clinical trial of a CAR-T therapy to treat a type of B-cell lymphoma died 52 days after infusion, sending CRSP stock plunging early Wednesday.